Athanasios J. Karoukis
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Athanasios J. Karoukis.
Proceedings of the National Academy of Sciences of the United States of America | 2010
Wei Chen; Dwight Stambolian; Albert O. Edwards; Kari Branham; Mohammad Othman; Johanna Jakobsdottir; Nirubol Tosakulwong; Margaret A. Pericak-Vance; Peter A. Campochiaro; Michael L. Klein; Perciliz L. Tan; Yvette P. Conley; Atsuhiro Kanda; Laura J. Kopplin; Yanming Li; Katherine J. Augustaitis; Athanasios J. Karoukis; William K. Scott; Anita Agarwal; Jaclyn L. Kovach; Stephen G. Schwartz; Eric A. Postel; Matthew Brooks; Keith H. Baratz; William L. Brown; Alexander J. Brucker; Anton Orlin; Gary C. Brown; Allen C. Ho; Carl D. Regillo
We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH (P < 10−75), ARMS2 (P < 10−59), C2/CFB (P < 10−20), C3 (P < 10−9), and CFI (P < 10−6). We compared our top findings with the Tufts/Massachusetts General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 controls) and genotyped 30 promising markers in additional individuals (up to 7,749 cases and 4,625 controls). With these data, we identified a susceptibility locus near TIMP3 (overall P = 1.1 × 10−11), a metalloproteinase involved in degradation of the extracellular matrix and previously implicated in early-onset maculopathy. In addition, our data revealed strong association signals with alleles at two loci (LIPC, P = 1.3 × 10−7; CETP, P = 7.4 × 10−7) that were previously associated with high-density lipoprotein cholesterol (HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis, we also observed association with AMD of HDL-c—associated alleles near LPL (P = 3.0 × 10−3) and ABCA1 (P = 5.6 × 10−4). Multilocus analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with the highest-risk genotypes were cases, and 85% of these had advanced AMD. Our studies extend the catalog of AMD associated loci, help identify individuals at high risk of disease, and provide clues about underlying cellular pathways that should eventually lead to new therapies.
Investigative Ophthalmology & Visual Science | 2012
Kari Branham; Mohammad Othman; Matthew Brumm; Athanasios J. Karoukis; Pelin Atmaca-Sonmez; Beverly M. Yashar; Sharon B. Schwartz; Niamh B. Stover; Karmen M Trzupek; Dianna H. Wheaton; Barbara J. Jennings; Maria Laura Ciccarelli; K. Thiran Jayasundera; Richard Alan Lewis; David G. Birch; Jean Bennett; Paul A. Sieving; Sten Andréasson; Jacque L. Duncan; Gerald A. Fishman; Alessandro Iannaccone; Richard G. Weleber; Samuel G. Jacobson; John R. Heckenlively; Anand Swaroop
PURPOSE To determine the proportion of male patients presenting simplex retinal degenerative disease (RD: retinitis pigmentosa [RP] or cone/cone-rod dystrophy [COD/CORD]) with mutations in the X-linked retinal degeneration genes RPGR and RP2. METHODS Simplex males were defined as patients with no known affected family members. Patients were excluded if they had a family history of parental consanguinity. Blood samples from a total of 214 simplex males with a diagnosis of retinal degeneration were collected for genetic analysis. The patients were screened for mutations in RPGR and RP2 by direct sequencing of PCR-amplified genomic DNA. RESULTS We identified pathogenic mutations in 32 of the 214 patients screened (15%). Of the 29 patients with a diagnosis of COD/CORD, four mutations were identified in the ORF15 mutational hotspot of the RPGR gene. Of the 185 RP patients, three patients had mutations in RP2 and 25 had RPGR mutations (including 12 in the ORF15 region). CONCLUSIONS This study represents mutation screening of RPGR and RP2 in the largest cohort, to date, of simplex males affected with RP or COD/CORD. Our results demonstrate a substantial contribution of RPGR mutations to retinal degenerations, and in particular, to simplex RP. Based on our findings, we suggest that RPGR should be considered as a first tier gene for screening isolated males with retinal degeneration.
Archives of Ophthalmology | 2010
Thiran Jayasundera; Kari Branham; Mohammad Othman; William Rhoades; Athanasios J. Karoukis; Hemant Khanna; Anand Swaroop; John R. Heckenlively
OBJECTIVES To assess the phenotype of patients with X-linked retinitis pigmentosa (XLRP) with RP2 mutations and to correlate the findings with their genotype. METHODS Six hundred eleven patients with RP were screened for RP2 mutations. From this screen, 18 patients with RP2 mutations were evaluated clinically with standardized electroretinography, Goldmann visual fields, and ocular examinations. In addition, 7 well-documented cases from the literature were used to augment genotype-phenotype correlations. RESULTS Of 11 boys younger than 12 years, 10 (91%) had macular involvement and 9 (82%) had best-corrected visual acuity worse than 20/50. Two boys from different families (aged 8 and 12 years) displayed a choroideremia-like fundus, and 9 boys (82%) were myopic (mean error, -7.97 diopters [D]). Of 10 patients with electroretinography data, 9 demonstrated severe rod-cone dysfunction. All 3 female carriers had macular atrophy in 1 or both eyes and were myopic (mean, -6.23 D). All 9 nonsense and frameshift and 5 of 7 missense mutations (71%) resulted in severe clinical presentations. CONCLUSIONS Screening of the RP2 gene should be prioritized in patients younger than 16 years characterized by X-linked inheritance, decreased best-corrected visual acuity (eg, >20/40), high myopia, and early-onset macular atrophy. Patients exhibiting a choroideremia-like fundus without choroideremia gene mutations should also be screened for RP2 mutations. CLINICAL RELEVANCE An identifiable phenotype for RP2-XLRP aids in clinical diagnosis and targeted genetic screening.
Frontiers of Medicine in China | 2018
Steven K. Lundy; Enayat Nikoopour; Athanasios J. Karoukis; Ray A. Ohara; Mohammad Othman; Rebecca Tagett; K. Thiran Jayasundera; John R. Heckenlively
Autoimmune retinopathy (AIR) causes rapidly progressive vision loss that is treatable but often is confused with other forms of retinal degeneration including retinitis pigmentosa (RP). Measurement of anti-retinal antibodies (ARA) by Western blot is a commonly used laboratory assay that supports the diagnosis yet does not reflect current disease activity. To search for better diagnostic indicators, this study was designed to compare immune biomarkers and responses toward the retinal protein, recoverin, between newly diagnosed AIR patients, slow progressing RP patients and healthy controls. All individuals had measurable anti-recoverin IgG and IgM antibodies by ELISA regardless of disease status or Western blot results. Many AIR patients had elevated anti-recoverin IgG1 levels and a strong cellular response toward recoverin dominated by IFNγ. RP patients and controls responded to recoverin with a lower IFNγ response that was balanced by IL-10 production. Both AIR and RP patients displayed lower levels of total peripheral blood mononuclear cells that were due to reductions of CD4+ TH cells. A comparison of messenger RNA (mRNA) for immune-related genes in whole blood of AIR patients versus RP patients or controls indicated lower expression of ATG5 and PTPN22 and higher expression of several genes involved in TH cell signaling/transcription and adhesion. These data indicate that an immune response toward recoverin is normal in humans, but that in AIR patients the balance shifts dramatically toward higher IFNγ production and cellular activation.
Investigative Ophthalmology & Visual Science | 2005
Radha Ayyagari; Nawajes A. Mandal; Athanasios J. Karoukis; Lianchun Chen; Ning C. McLaren; Mona Lichter; David Wong; Peter F. Hitchcock; Rafael C. Caruso; Irene H. Maumenee; Paul A. Sieving
Archives of Ophthalmology | 2007
Katy Downs; David N. Zacks; Rafael C. Caruso; Athanasios J. Karoukis; Kari Branham; Beverly M. Yashar; Mark H. Haimann; Karmen M Trzupek; Meira Meltzer; Delphine Blain; Julia E. Richards; Richard G. Weleber; John R. Heckenlively; Paul A. Sieving; Radha Ayyagari
JAMA Ophthalmology | 2013
Sarwar Zahid; Naheed W. Khan; Kari Branham; Mohammad Othman; Athanasios J. Karoukis; Nisha Sharma; Ashley Moncrief; Mahdi N. Mahmood; Paul A. Sieving; Anand Swaroop; John R. Heckenlively; Thiran Jayasundera
Investigative Ophthalmology & Visual Science | 2003
Shahrokh C. Khani; Athanasios J. Karoukis; Joyce E. Young; Rajesh Ambasudhan; Tracy Burch; Richard Stockton; Richard Alan Lewis; Lori S. Sullivan; Stephen P. Daiger; Elias Reichel; Radha Ayyagari
Investigative Ophthalmology & Visual Science | 2010
Matthew Brumm; Kari Branham; Mohammad Othman; Athanasios J. Karoukis; Richard G. Weleber; Alessandro Iannaccone; Samuel G. Jacobson; Anand Swaroop; John R. Heckenlively
Investigative Ophthalmology & Visual Science | 2004
Catherine A. Downs; Athanasios J. Karoukis; M. Haimann; David N. Zacks; Radha Ayyagari